Receptors and older hypotheses

DXM FAQ 1997: selective audit by topic

What is known about NMDA, sigma-1 and sigma-2; how to read older PCP2 labels and the receptor ladder.

DXM / DXO · Ki · µM

Xiao et al. table, audit §4. A common logarithmic axis; further left is a lower Ki in that assay.

The table compares Ki values from different biological systems. Ki describes binding; functional potency, clinical effect and brain target occupancy are distinct characteristics.

NMDA

● DXM 1.59 · ■ DXO 0.22 · n in the article = 4

σ1

● DXM 1.67 · ■ DXO 2.85 · n in the article = 2

α3β4 nAChR

● DXM 14.70 · ■ DXO 9.98 · n in the article = 2

SERT

● DXM 0.0084 · ■ DXO 0.14 · n in the article = 2

NET

● DXM 20.51 · ■ DXO 5.67 · n in the article = 2

n is the number of experiments reported in this article.

This is a preclinical study of deuterated DXM with bupropion. All authors disclosed employment at Salubris. The conflict of interest requires disclosure and independent confirmation of the conclusions, but does not in itself invalidate the table. 8

Audit reference №8 · Assay systems and conflict of interest · Plasma concentration and receptor occupancy

PCP2 and the dopamine hypothesis

PCP2 is an older label for binding sites. Its association with DAT and its use to explain the first plateau remain hypotheses.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Meoni studied dextromethorphan binding sites in rat brain and obtained evidence linking part of the observations to serotonin transport. Xiao’s modern paper examines several known targets.

Limits of the conclusion: Establishing a molecular target requires independent evidence on the identity of the site and the function of the protein.

Sources: Xiao — DXM and DXO target binding Meoni — DM2 binding sites

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.2 White proposed a link between PCP2 and dopamine reuptake.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.2 · Contribution of the PCP2 Binding Site

The second binding site: what was clarified

DM2 findings are better described through the conditions of the particular experiment. Some older observations are consistent with sites associated with serotonin transport.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: In Meoni’s rat-brain study, binding was sodium-dependent; distribution and mutual displacement with paroxetine supported an association with the serotonin uptake system.

Limits of the conclusion: The older labels grouped different experimental observations. Each site requires its own molecular identification.

Sources: Meoni — DM2 binding sites

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.1 The FAQ links the second DXM binding site to PCP2 with near certainty.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.1 · General Information

Sigma receptors gained a molecular description

The structure of sigma-1 was later published, and sigma-2 was identified as TMEM97. These discoveries update the older description.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schmidt presented the crystal structure of human sigma-1. Alon showed that TMEM97 corresponds to sigma-2.

Limits of the conclusion: Molecular descriptions help investigate receptor functions. Receptor function and a particular subjective effect belong to different levels of description.

Sources: Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97

Historical paraphrase · FAQ 4.0 · 1997 · §10.2 The FAQ reflects early uncertainty about the cellular location and nature of sigma receptors.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2 · What are Sigma Receptors?

Sigma receptors and unusual sensations of movement

This explanation remains a hypothesis. Sigma-1 findings in experimental models and prescription labeling concern other endpoints.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Nguyen examined antidepressant-like effects of DXM in a mouse model. The Auvelity label describes DXM’s pharmacological targets and notes uncertainty about the mechanism of therapeutic action.

Limits of the conclusion: A mouse behavioral model and human subjective experiences require different methods of evaluation.

Sources: Nguyen — mouse model Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §10.2.1.2 White linked unusual sensations of movement to sigma activity.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.1.2 · Location and Function in the Brain

The historical sigma-3 label

This audit retains sigma-3 as a historical label. The modern molecular classification in the cited sources centers on sigma-1 and sigma-2.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Schmidt’s structural work and Alon’s identification of TMEM97 provide testable grounds for the modern names.

Limits of the conclusion: The audit’s source coverage is limited. A separate new target requires confirmed molecular identification.

Sources: William White — historical DXM FAQ Schmidt — sigma-1 structure Alon — sigma-2 and TMEM97

Historical paraphrase · FAQ 4.0 · 1997 · §10.2.3 The FAQ mentions sigma-3 as a recently discovered site.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.2.3 · Sigma 3 Receptors

Endopsychosin: an unresolved hypothesis

In the audit, this remains an unconfirmed historical hypothesis. It offers a weak basis for explaining modern DXM findings.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: For this row, the audit cites the FAQ itself. Its bibliography contains no separate modern primary confirmation.

Limits of the conclusion: This describes the sources in the audit’s bibliography; a comprehensive literature search on the hypothesis lies outside its scope.

Sources: William White — historical DXM FAQ

Historical paraphrase · FAQ 4.0 · 1997 · §10.7 White discussed a proposed endogenous ligand called endopsychosin.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §10.7 · Endopsychosin and the Big Picture

The role of NMDA in dissociative effects

The main association remains valid. DXM and DXO differ in binding profiles, while each target’s precise contribution to human effects remains a research question.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Carbonaro’s and Shram’s papers describe controlled studies of DXM effects in humans. Xiao provides in-vitro binding data; the Auvelity label includes NMDA in its pharmacology description.

Limits of the conclusion: Plasma concentration, laboratory affinity and receptor occupancy in the brain are different measures. Relating them requires an appropriate model and data.

Sources: Xiao — DXM and DXO target binding Carbonaro — DXM effects in humans Shram — ketamine comparison Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §9.2.4 The FAQ gives NMDA an important role in dissociative effects.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.2.4 · Contribution of the NMDA Receptor

The receptor activation ladder

The scheme is best retained as a historical model. DXM and DXO concentrations, binding and functional effects describe different aspects of the substances’ actions.

Remains a hypothesis

According to the 2026 audit · edition

Evidence and limitations

What was examined: Xiao compares DXM and DXO targets in vitro. These measurements differ from receptor-occupancy data in the living brain.

Limits of the conclusion: The original scheme was a qualitative proposal. This audit provides no established thresholds for sequential target activation across plateaus.

Sources: William White — historical DXM FAQ Xiao — DXM and DXO target binding

Historical paraphrase · FAQ 4.0 · 1997 · §9.3.1 White proposed a qualitative sequence of target involvement, including PCP2, and qualified it as approximate.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.3.1 · Plateaus 1-3: Multiple Receptors

Sources for this topic
  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Xiao — DXM and DXO target binding — Selected paper sections

    The abstract, target-binding table and conflict-of-interest disclosure were checked; the authors are employees of the compound’s developer.

  3. Meoni — DM2 binding sites — PubMed abstract
  4. Schmidt — sigma-1 structure — PubMed abstract
  5. Alon — sigma-2 and TMEM97 — PubMed abstract
  6. Nguyen — mouse model — PubMed abstract
  7. Carbonaro — DXM effects in humans — PubMed abstract
  8. Shram — ketamine comparison — PubMed abstract
  9. Auvelity — current label — Official label

    Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.

All update topics · Review coverage

Reference

Open the source and related combinations →